1.12
+0.005(+0.45%)
Currency In USD
| Previous Close | 1.11 |
| Open | 1.1 |
| Day High | 1.13 |
| Day Low | 1.09 |
| 52-Week High | 21.49 |
| 52-Week Low | 0.96 |
| Volume | 112,495 |
| Average Volume | 778,875 |
| Market Cap | 5.74M |
| PE | -0.21 |
| EPS | -5.33 |
| Moving Average 50 Days | 1.13 |
| Moving Average 200 Days | 1.86 |
| Change | 0.01 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $11 as of October 14, 2025 at a share price of $1.115. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $684.05 as of October 14, 2025 at a share price of $1.115.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology
GlobeNewswire Inc.
Oct 09, 2025 12:45 PM GMT
With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opport
Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System
GlobeNewswire Inc.
Sep 29, 2025 1:15 PM GMT
GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA applicati
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress
GlobeNewswire Inc.
Sep 09, 2025 1:00 PM GMT
Presentation to highlight findings from the first phase of the Company’s ongoing first-in-human proof-of-concept (PoC) clinical trial THE WOODLANDS, TX, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “